Evidence map›Paper›PMID 41842944›Full record

ArticleJCI insight2026

Position-5-driven reorientation of an immunodominant HLA-A*24:02 SARS-CoV-2 epitope drives universal T cell escape.

Takeshi Nakama, Aaron Wall, Garry Dolton, Li Rong Tan, Hannah Thomas, Hiroshi Hamana, Yoshiki Aritsu, Toong Seng Tan, Mako Toyoda, Yoshihiko Goto and 14 more

Abstract read
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Takeshi NakamaDivision of Infection and Immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
Aaron WallDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales, United Kingdom.
Garry DoltonDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales, United Kingdom.
Li Rong TanDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales, United Kingdom.
Hannah ThomasDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales, United Kingdom.
Hiroshi HamanaDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
Yoshiki AritsuDivision of Infection and Immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
Toong Seng TanDivision of Infection and Immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
Mako ToyodaDivision of Infection and Immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
Yoshihiko GotoDivision of Infection and Immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
Huanyu LiDivision of Infection and Immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
Mizuki KitamatsuDepartment of Applied Chemistry, Faculty of Science and Engineering, Kindai University, Osaka, Japan.
Keiko UdakaDepartment of Immunology, Kochi University, Kochi, Japan.
Yusuke MiyashitaDepartment of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, and.
Hiroyuki OshiumiDepartment of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, and.
Kimitoshi NakamuraDepartment of Pediatrics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Yoji NagasakiDivision of Infectious Diseases, Clinical Research Institute, NHO, Kyushu Medical Center, Fukuoka, Japan.
Rumi MinamiInternal Medicine, Clinical Research Institute, NHO, Kyushu Medical Center, Fukuoka, Japan.
Hirotomo NakataDepartment of Hematology, Rheumatology and Infectious Diseases, Kumamoto University School of Medicine, Kumamoto University Hospital, Kumamoto, Japan.
Pierre J RizkallahDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales, United Kingdom.
Hiroyuki KishiDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
Takamasa UenoDivision of Infection and Immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
Andrew K SewellDivision of Infection and Immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
Chihiro MotozonoDivision of Infection and Immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytotoxic T lymphocytes form a critical component of SARS-CoV-2 immunity by recognizing viral peptides bound to HLA class I molecules. Here, we identified the spike-derived peptide NYNYLYRLF448-456 (NF9) as the immunodominant HLA-A*24:02-restricted epitope in both convalescent and vaccinated donors. Across cohorts, A24/NF9-specific responses were dominated by public TCR motifs featuring TRAV12-1 paired with TRBJ2-7 and a conserved CDR3β sequence (CASSXXXGYEQYF). Using a panel of 13 TCRs, we mapped recognition of single amino acid substitutions within NF9 and identified residue 5 (L452) as the principal determinant of escape. The L452R substitution, characteristic of the Delta variant, abolished recognition across all tested TCRs despite preserved HLA binding. Crystallography of a representative public TCR (P1-15) revealed that mutation at position-5 reoriented the peptide within HLA-A*24:02, flipping the adjacent Y453 side chain into the peptide-binding groove and eliminating the dominant TCR contact. This position-5-driven conformational switch provided a structural mechanism for universal loss of NF9 recognition by HLA-A*24:02-restricted T cells. Consistent with this, Delta-infected convalescents failed to mount de novo NF9-5R-specific responses while retaining responses to the conserved A24/QI9 spike epitope. Together, these findings defined the basis of A24/NF9 recognition and showed how 1 mutation remodeled peptide presentation to abrogate TCR responses.

Indexed as

COVID-19Epitopes, T-LymphocyteHLA-A24 AntigenImmunodominant EpitopesSARS-CoV-2Spike Glycoprotein, CoronavirusT-Lymphocytes, CytotoxicHumansEpitopes, T-LymphocyteHLA-A*24:02 antigenHLA-A24 AntigenImmunodominant EpitopesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19ImmunologyInfectious diseaseT cell receptorT cells

Identifiers

PMID41842944
PMCPMC13232003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.